Genscript Biotech Corporation
(*Incorporated in the Cayman Islands with limited liability*)
(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE

This is a voluntary announcement made by Genscript Biotech Corporation (the "**Company**").

The board of directors (the "**Board**") of the Company is pleased to announce that on November [5], 2024 (after trading hours on November 5, 2024 in Hong Kong), Legend Biotech Corporation ("**Legend Biotech**"), an associate of the Company, whose shares are listed by way of American Depository Shares on the Nasdaq Global Selected Market in the United States, announced that new data will be presented on minimal residual disease (MRD) negativity rates from the Phase 3 CARTITUDE-4 trial in multiple myeloma patients treated with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus standard of care (SoC). The study evaluated lenalidomide-refractory patients who have received one to three prior lines of therapy and will be featured in an oral presentation on Monday, December 9, 2024, at 5:45 p.m. PT at the 66th American Society of Hematology Annual Meeting in San Diego.

Data from CARTITUDE-4 supported the U.S. Food and Drug Administration (the "**FDA**") and the European Commission (the "**EC**") approval of CARVYKTI® earlier this year for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy (LOT), including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), and are refractory to lenalidomide. CARVYKTI® is the first and only BCMA-targeted CAR-T cell therapy approved for the treatment of patients with multiple myeloma who have had at least one prior line of therapy. Globally, CARVYKTI is now commercially available in five countries and has been utilized by over 4,000 patients.

Oral and poster presentation abstracts from the meeting can be founded below.

Abstract Title	Authors	Session Details
Ciltacabtagene Autoleucel (Cilta-cel) vs Standard of Care (SoC) in Patients with Lenalidomide-Refractory Multiple Myeloma (MM) After 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 CARTITUDE-4 Trial	Rakesh Popat, Albert Oriol, Michele Cavo, Lionel Karlin, Irit Avivi, Wilfried Roeloffzen, Seok Jin Kim, Brea Lipe, Noffar Bar, Noemi Horvath, Andrew Spencer, Chang Ki Min, Diana Chen, Quanlin Li, Katherine Li, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, Martin Vogel, Nikoletta Lendvai, Tamar Lengil, Nitin Patel, Octavio Costa Filho, Erika Florendo, Yi Lin	**ORAL 1032** **Session Name**: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma **Session Date:** Monday, December 9, 2024 **Session Time:** 4:30 p.m. - 6:00 p.m. **Presentation Time:** 5:45 p.m. - 6:00 p.m. PT **Room:** Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene autoleucel (Cilta-cel) Versus Standard of Care for Patients With Lenalidomide-Refractory Multiple Myeloma: Results From the Phase 3 CARTITUDE-4 Clinical Trial	Noffar Bar, Roberto Mina, Anne K. Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C. Minnema, Leyla Shune, Iris Isufi, Simon J. Harrison, Urvi A. Shah, André De Champlain, Katherine S. Gries, Diana Chen, Quanlin Li, Tzu-Min Yeh, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, William Deraedt, Martin Vogel, Nikoletta Lendvai, Nitin Patel, Octavio Costa Filho, Erika Florendo, Lionel Karlin, Katja Weisel	**POSTER 2002** **Session Name:** 655. Multiple Myeloma: Cellular Therapies: Poster I **Session Date:** Saturday, December 7, 2024 **Presentation Time:** 6:00 p.m. - 8:00 p.m. PT **Room:** San Diego Convention Center, Halls G-H
Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With 2–4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison	Nieves Lopez-Muñoz, Noffar Bar, Joris Diels, Suzy Van Sanden, João Mendes, Seina Lee, Teresa Hernando, Nikoletta Lendvai, Nitin Patel, Tadao Ishida, Jeremy Er, Simon J. Harrison, Urvi Shah	**POSTER 3390** **Session Name:** 655. Multiple Myeloma: Cellular Therapies: Poster II **Session Date:** Sunday, December 8, 2024 **Presentation Time:** 6:00 p.m. - 8:00 p.m. PT **Room:** San Diego Convention Center, Halls G-H
Efficacy of CARVYKTI in CARTITUDE-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting	Rafael Fonseca, Joris Diels, Francesca Ghilotti, João Mendes, Teresa Hernando, Seina Lee, Jordan M. Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Winfried Alsdorf, Margherita Ursi	**POSTER 2005** **Session Name:** 655. Multiple Myeloma: Cellular Therapies: Poster I **Session Date:** Saturday, December 7, 2024 **Presentation Time:** 5:30 p.m. - 7:30 p.m. PT **Room:** San Diego Convention Center, Halls G-H

For details of the important safety information, warnings and precautions and prescribing information of CARVYKTI®, please refer to the press release as published on Legend Biotech's website available at https://investors.legendbiotech.com/node/8831/pdf.

ABOUT CARVYKTI® (CILTACABTAGENE AUTOLEUCEL; CILTA-CEL)

Ciltacabtagene autoleucel is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient's own T-cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express BCMA. The cilta-cel CAR protein features two BCMA-targeting single domain antibodies designed to confer high avidity against human BCMA. Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells.

In December 2017, Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize cilta-cel. In February 2022, cilta-cel was approved by the U.S. Food and Drug Administration (FDA) under the brand name CARVYKTI® for the treatment of adults with relapsed or refractory multiple myeloma. In April 2024, cilta-cel was approved for the second-line treatment of patients with relapsed/refractory myeloma who have received at least one prior line of therapy including a proteasome inhibitor, an immunomodulatory agent, and are refractory to lenalidomide.

In May 2022, the European Commission (EC) granted conditional marketing authorization of CARVYKTI® for the treatment of adults with relapsed and refractory multiple myeloma. In September 2022, Japan's Ministry of Health, Labour and Welfare (MHLW) approved CARVYKTI®. Cilta-cel was granted Breakthrough Therapy Designation in the U.S. in December 2019 and in China in August 2020. In addition, cilta-cel received a PRIority MEdicines (PRIME) designation from the European Commission in April 2019. Cilta-cel also received Orphan Drug Designation from the U.S. FDA in February 2019, from the European Commission in February 2020, and from the Pharmaceuticals and Medicinal Devices Agency (PMDA) in Japan in June 2020. In March 2022, the European Medicines Agency's Committee for Orphan Medicinal Products recommended by consensus that the orphan designation for cilta-cel be maintained on the basis of clinical data demonstrating improved and sustained complete response rates following treatment.

ABOUT CARTITUDE-4

CARTITUDE-4 (NCT04181827) is an ongoing, international, randomized, open-label Phase 3 study evaluating the efficacy and safety of cilta-cel versus pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) in adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy, including a PI and an IMiD.

ABOUT MULTIPLE MYELOMA

Multiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excessive proliferation of plasma cells. In 2024, it is estimated that more than 35,000 people will be diagnosed with multiple myeloma, and more than 12,000 people will die from the disease in the U.S. While some patients with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone problems, low blood counts, calcium elevation, kidney problems or infections.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements in this announcement about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech's strategies and objectives; statements relating to CARVYKTI®, including Legend Biotech's expectations for CARVYKTI® and its therapeutic potential; statements related to the potential results from ongoing studies in the CARTITUDE clinical development program; and the potential benefits of Legend Biotech's product candidates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by Legend Biotech's third party partners; uncertainties arising from challenges to Legend Biotech's patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the "Risk Factors" section of Legend Biotech's Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 19, 2024. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this announcement as anticipated, believed, estimated or expected. Any forward-looking statements contained in this announcement speak only as of the date of this announcement. The Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, November 5, 2024

*As at the date of this announcement, the executive Directors are Dr. Fangliang Zhang ("**Dr. Frank Zhang**"), Mr. Jiange Meng ("**Mr. Robin Meng**"), Ms. Ye Wang ("**Ms. Sally Wang**") and Dr. Li Zhu; the non-executive Directors are Dr. Luquan Wang ("**Dr. Larry Wang**") and Dr. Ross Grossman; and the independent non-executive Directors are Mr. Zumian Dai ("**Mr. Edward Dai**"), Mr. Jiuan Pan ("**Mr. Ethan Pan**"), Mr. Yiu Leung Andy Cheung, Dr. Chenyang Shi ("**Dr. Victor Shi**") and Dr. Alphonse Galdes.*